Acalabrutinib-Venetoclax-Obinutuzumab for High-Risk CLL
February 20, 2025
Acalabrutinib, venetoclax, and obinutuzumab is a highly active, time-limited frontline therapy for patients with high-risk CLL.
Acalabrutinib, venetoclax, and obinutuzumab is a highly active, time-limited frontline therapy for patients with high-risk CLL.
The AMPLIFY trial of acalabrutinib plus venetoclax, with or without obinutuzumab, could lead to the FDA approval of the first all-oral frontline CLL therapy.
Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.
Resistance mutations in BTK and PLCG2 are common in patients with CLL who progress on acalabrutinib, a BTK inhibitor treatment that is taken continuously.
An interim analysis of the AMPLIFY trial comparing acalabrutinib and venetoclax with or without obinutuzumab for CLL shows improvements in patient survival.
A Matching-Adjusted Indirect Comparison (MAIC) Case Study: Zanubrutinib vs. Acalabrutinib Education Activity
Acalabrutinib may be taken alone or in combination with obinutuzumab as a preferred initial (first-line) treatment, or alone as a second- or thirdline treatment.
Zanubrutinib is an excellent option for patients with CLL / SLL who are unable to tolerate acalabrutinib due to side effects.
Acalabrutinib has a low risk of sudden death and ventricular arrhythmias in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) patients.